Clinical trials: Benign Prostatic Hyperplasia (BPH)
Benign Prostate Hyperplasia
Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia
Efficacy and Safety of Tamsulosin/Solifenacin Combination therapy in Patients with voiding symptoms and moderate to severe storage symptoms due to Benign Prostate Hyperplasia : a randomized, double blinded, parallel design…
- Trial name
- NCT02827578
- Testing
- Tamsulosin, Solifenacin
- Where
- South Korea
- Volunteers
- 588 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Prostatic Hyperplasia, Prostate
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems
Study to look at safety and effectiveness of different doses of tadalafil on prostate related genital/urinary tract problems.
- Trial name
- PILUTS (NCT00547625)
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Study in Benign Prostatic Hyperplasia
The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured…
- Trial name
- NCT01152190
- Testing
- Tadalafil
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase III Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients.
- Trial name
- NCT03246880
- Testing
- Tamsulosin 0.2mg, Tadalafil 5mg
- Where
- South Korea
- Volunteers
- 455 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Nocturia, Benign Prostatic Hypertrophy (BPH)
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
The purpose of this study is to establish the dose response relationship of VA106483 and nocturnal urine volumes in a population of elderly male subjects with Benign Prostatic Hypertrophy (BPH) who are likely to present with…
- Trial name
- NCT01330927
- Testing
- VA106483
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Vantia Ltd
Urinary Calculi, Benign Prostatic Hyperplasia
Flexiva Pulse Registry
To obtain post-market safety and efficacy data for FlexivaTM Pulse High Power Single-Use Laser Fibers during lithotripsy and soft tissue procedure of holmium laser enucleation of the prostate (HoLEP).
- Trial name
- NCT05027971
- Testing
- Flexiva Pulse High Power Single-Use Laser Fibers
- Where
- 4 sites in United States
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia
This study has 4 phases: screening phase (visit 1), treatment phase (visit 2 - 6 mths after treatment initiation), and end of treatment phase (visit 3 - end of year 1).
- Trial name
- NCT00593593
- Volunteers
- 1,000 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
A Study of Tadalafil in Benign Prostatic Hyperplasia
The purpose of this study is to investigate the pharmacokinetics of tadalafil in Japanese and non-Japanese men with Benign Prostatic Hyperplasia (BPH). The safety of tadalafil will also be studied.
- Trial name
- NCT01183650
- Testing
- Tadalafil
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Bladder Outlet Obstruction
Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration "Holter"
Current gold standard of bladder outlet diagnosis is pressure flow study. This study is invasive time consuming and requires expensive and complex set-up.
- Trial name
- NCT01779349
- Testing
- Dynamic Urine Vibration "Holter"
- Where
- 2 sites in Israel
- Volunteers
- 45 people
- Sponsor
- P. Square Medical Ltd
Prostatic Hyperplasia, Urinary Bladder, Overactive
A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031
To investigate the safety and overall tolerability of co-administration two PDE5 inhibitors UK369,003 and sildenafil
- Conditions
- Prostatic Hyperplasia, Urinary Bladder, Overactive, Erectile Dysfunction
- Trial name
- NCT00814736
- Testing
- UK369,003, sildenafil
- Where
- Singapore
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Benign Prostatic Hypertrophy
Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and…
- Trial name
- NCT00663858
- Testing
- Cetrorelix 78+78
- Where
- 54 sites in Belarus, Bulgaria and 8 more
- Volunteers
- 420 people
- Sponsor
- AEterna Zentaris
Prostatism, Erectile Dysfunction
Study of Dr. Pyke's Supplement for Stream (S4S) in Men With Prostatism and ED
This is the first clinical trial of Dr. Pyke's Supplement for Stream (S4S), a proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3, to investigate its effects on prostatism and erections…
- Trial name
- S4S4BPH/ED (NCT03681392)
- Testing
- Dr. Pyke's Supplement for Stream (S4S)
- Sponsor
- Robert E. Pyke
Benign Prostatic Hyperplasia
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
APEX is a prospective multi-site registry of real-world experience with the Optilume™ BPH Catheter System for treatment of men experiencing symptomatic BPH.
- Trial name
- APEX (NCT06560476)
- Testing
- Data collection
- Where
- 8 sites in United States
- Volunteers
- 500 people
- Sponsor
- Urotronic Inc.
Bladder Neck Obstruction, Benign Prostate Hyperplasia
Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia
The purpose of this study is to assess the safety and efficacy of MediTate Temporary Implantable Nitinol Device (TIND) used to alleviate symptoms of Bladder Outlet Obstruction (BOO) secondary to Benign Prostate Hyperplasia…
- Trial name
- NCT01436877
- Testing
- Insertion of Temporary Implantable Nitinol Device (TIND)
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- Medi-Tate Ltd.
Benign Prostatic Hyperplasia
Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression
The purpose of this study is: To assess safety of Afalaza drug within 12 months in patients with symptoms of benign prostatic hyperplasia (BPH) and risk of progression.
- Trial name
- NCT01716104
- Testing
- Afalaza
- Where
- 16 sites in Russia, Ukraine
- Volunteers
- 260 people
- Sponsor
- Materia Medica Holding
Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation
This is an open-label, single-arm, prospective interventional study to assess the tolerability and efficacy of Harnalidge® OCAS® 0.4 mg in Taiwan patients who are unsatisfied with tamsulosin 0.2 mg for the treatment of lower…
- Trial name
- NCT02180789
- Testing
- Tamsulosin OCAS
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
- Trial name
- NCT00224120
- Testing
- Silodosin
- Where
- 42 sites in United States
- Volunteers
- 462 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia, Overactive Bladder
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms…
- Trial name
- PLUS (NCT02757768)
- Testing
- Mirabegron, Tamsulosin Hydrochloride
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 715 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostatic Hyperplasia
Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study
Primary: To assess improvement in ejaculation from baseline to the end of treatment (Week 12 or premature withdrawal) with Alfuzosin 10mg OD, using MSHQ score.
- Trial name
- NCT00427882
- Testing
- ALFUZOSIN
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Handok Inc.
Benign Prostatic Hyperplasia
Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter
The purpose of this study is to evaluate the efficacy and safety of dutasteride at reducing relapse rates of Acute Urinary Retention (AUR), including reduction in surgical intervention for benign prostatic hyperplasia (BPH), in…
- Trial name
- NCT00421421
- Testing
- Dutasteride
- Where
- 25 sites in United Kingdom
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline